Paper Details

  1. Home
  2. Paper Details

The Nonsteroidal Mineralocorticoid-Receptor-Antagonist Finerenone in Cardiorenal Medicine: A State-of-the-Art Review of the Literature.

Author: AgarwalRajiv, GeorgianosPanagiotis I

ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, has been approved for cardiorenal protection in patients with CKD associated with T2DM. Two phase 3 clinical trials, FIDELIO-DKD and FIGARO-DKD, demonstrated its efficacy in reducing cardiovascular and kidney failure risks.
Paper Details　
Original Abstract of the Article :
Steroidal mineralocorticoid-receptor-antagonists (MRAs), such as spironolactone and eplerenone, are guideline-directed therapies in patients with heart failure with reduced ejection fraction or resistant hypertension. However, the associated risk of hyperkalemia and hormonal side effects limit their...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9951054/

データ提供：米国国立医学図書館（NLM）

Finerenone: A Novel Nonsteroidal MRA for Cardiorenal Protection

Cardiorenal disease is a growing concern, and this research explores the potential of a novel nonsteroidal mineralocorticoid-receptor antagonist (MRA), finerenone, in protecting against cardiovascular and kidney complications. This state-of-the-art review of the literature highlights the promising clinical trial data supporting the efficacy and safety of finerenone.

Finerenone: A Potential Solution for Cardiorenal Protection

The review highlights the potential of finerenone in reducing the risk of cardiovascular and kidney failure outcomes in patients with type 2 diabetes mellitus and chronic kidney disease. This research is like a refreshing oasis in the desert of cardiorenal disease, offering a potential new approach to managing this complex condition.

A New Era in Cardiorenal Management

The development of finerenone represents a significant advancement in the field of cardiorenal medicine. Just as a camel adapts to the harsh desert environment, finerenone offers a more adaptable solution for managing cardiorenal disease, with a lower risk of hyperkalemia and other side effects compared to traditional MRAs. This research is a beacon of hope for a new era in cardiorenal care, offering potentially better outcomes for patients.

Dr.Camel's Conclusion

The vast desert of cardiorenal disease requires constant exploration and innovation. Finerenone emerges as a promising oasis, offering a new approach to protecting against cardiovascular and kidney complications. This research is a testament to the ongoing efforts to improve patient outcomes, ensuring a healthier future for those navigating the complex terrain of cardiorenal disease.

Date :
  1. Date Completed 2023-02-27
  2. Date Revised 2023-11-05
Further Info :

Pubmed ID

36331811

DOI: Digital Object Identifier

PMC9951054

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.